Personalized tamoxifen: a step closer but miles to go.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Aditya Bardia, Vered Stearns

Abstract

Genetic variants in CYP2D6 lead to reduced conversion of tamoxifen to the active metabolite endoxifen. However, the role of the CYP2D6 genotype in predicting tamoxifen-associated outcomes remains controversial. Accurate assignment of the CYP2D6 genotype in archival tissues is crucial for future studies attempting to determine risk prediction of outcomes in tamoxifen-treated individuals.

References

Sep 17, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Matthew P GoetzJames N Ingle
Nov 20, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Yan JinVered Stearns
Aug 4, 2009·The Lancet Oncology·Timothy L LashStephen Hamilton-Dutoit
Sep 29, 2009·Cancer Biology & Therapy·Suresh MohlaPeter Nelson
Jun 3, 2010·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Werner SchrothHiltrud Brauch

❮ Previous
Next ❯

Citations

Jan 27, 2015·Cancer Treatment Reviews·Lisette BinkhorstTeun van Gelder

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Genomics (Keystone)

Cancer genomics approaches employ high-throughput technologies to identify the complete catalog of somatic alterations that characterize the genome, transcriptome and epigenome of cohorts of tumor samples. Discover the latest research using such technologies in this feed.

Related Papers

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
W NewmanD Gareth Evans
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Werner SchrothHiltrud Brauch
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
William J IrvinLisa A Carey
© 2021 Meta ULC. All rights reserved